Wall Street's main indexes ended mostly lower on Monday, with the Dow Jones Industrial Average and the S&P 500 giving back ground amid declines in oil prices , while the Nasdaq Composite bucked the weaker trend to reach a record high.
The blue-chip Dow again pulled back from the key 20,000 level, which it came within a point of during Friday's session. Conversely the Nasdaq has now climbed for five straight days as health and technology components led the way. The S&P's health group rose 0.5% in the best gain among the 11 sectors.
Benchmark US oil futures were trading almost 4% lower late in the day at $51.88 a barrel, the weakest since mid December. Energy stocks fell 1.4% in the largest loss among the sectors on the S&P 500 while oil major Exxon Mobil ( XOM ) posted the steepest decline among the two-thirds of the 30 blue-chips that retreated on the Dow.
Financials slid 0.8% as UK banks including Royal Bank of Scotland ( RBS ) and Lloyds Banking Group ( LYG ) posted declines following comments by Prime Minister Theresa May over the weekend that were perceived as possibly signalling a so-called hard Brexit, which would mean cutting ties to the single market of the European Union when Britain withdraws from the bloc.
On Tuesday, the calendar has the November Job Openings and Labor Turnover survey (JOLTS) and November wholesale trade due at 10 a.m. ET.
Here's where the markets stood by the close:
Dow Jones Industrial Average was up 76.42 points (-0.38%)
S&P 500 was up 8.08 points (-0.35%)
Nasdaq Composite Index was up 10.76 points (+0.19%)
FTSE 100 was up 0.38%
Nikkei 225 was closed
Hang Seng Index was up 0.25%
Shanghai China Composite Index was up 0.54%
(+) ARIA (+72.8%) To be acquired by Takeda Pharmaceutical for $5.2 billion
(+) MSTX (+64.3%) To merge with Savara in all-stock deal
(+) WOOF (+28.3%) To be acquired by Mars for $9.1 billion
(+) NBY (+10.6%) Provides upbeat Q4 sales estimates
(+) FCAU (+1.44%) Announces $1 billion of investments in US plants
(-) AMAG (-35.6%) Q4 sales below street estimates, entered exclusive development and marketing rights deal with PalatinTechnologies ( PTN )
(-) ADHD (-13.9%) Agrees with FDA on review of available data from phase 3 Measure study in a future NDA submission
(-) RWLK (-7.4%) Plans to cut operating expenses by 30% by cutting staff and corporate spending
(-) VMW (-1.17%) UBS downgrades to neutral from buy